Impact of obesity on incident hypertension independent of weight gain among nonhypertensive Japanese: The Ibaraki Prefectural Health Study (IPHS)

Ibaraki Health Plaza, Ibaraki Health Service Association, University of Tsukuba, Ibaraki, Japan.
Journal of Hypertension (Impact Factor: 4.72). 04/2012; 30(6):1122-8. DOI: 10.1097/HJH.0b013e328352b879
Source: PubMed


The aim of this study was to examine the association between BMI and risk of incident hypertension among Japanese men and women who are middle-aged and older.
Prospective, population-based cohort study.
A total of 68 205 nonhypertensive adults (18 336 men and 49 869 women) aged 40-79 years who completed health check-ups in the Ibaraki prefecture, Japan, in 1993 were followed up through 2006. To exclude the impact of BMI change during the follow-up period, a time-dependent covariate Cox proportional hazards model was used to compute the hazard ratios of incident hypertension according to BMI categories. Incident hypertension was defined as a SBP of at least 140 mmHg, a diastolic BP of at least 90 mmHg, and/or hypertensive medication use.
A total of 30 982 adults (45.4%) developed hypertension (9331 men and 21 651 women) during a mean of 3.9 years of follow-up. Compared with a BMI of less than 19.0, time-dependent covariates adjusted hazard ratios [95% confidence interval (CI)] for hypertension among participants with a BMI of at least 25.0 were 1.42 (1.17-1.73) for men aged 40-59 years, 1.34 (1.19-1.51) for men aged 60-79 years, 1.47 (1.33-1.62) for women aged 40-59 years, and 1.29 (1.18-1.41) for women aged 60-79 years.
The baseline BMI is associated with future risk for incident hypertension even after accounting for weight change during the follow-up period. Weight loss may be recommended to nonhypertensive obese adults to prevent the development of hypertension.

Download full-text


Available from: Takehiko Tsujimoto, Jul 18, 2014

  • No preview · Article · Jun 2012 · Journal of Hypertension
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Experimental and observational studies suggest a role for uric acid in non-alcoholic fatty liver disease (NAFLD). We examined the association between serum uric acid levels and NAFLD in a large population-based study from the United States. Materials/methods: A cross-sectional analysis of 10,732 nondiabetic adults who participated in the National Health and Nutrition Examination Survey 1988-1994. Sex specific uric acid quartiles were defined: ≤5.2, 5.3-6.0, 6.1-6.9, and >6.9mg/dL for men and ≤3.7, 3.8-4.5, 4.6-5.3, and >5.3mg/dL for women. NAFLD presence and severity were defined by ultrasonographic detection of steatosis in the absence of other liver diseases. We modeled the probability that more severe NAFLD would be associated with the highest quartiles of uric acid. Results: Compared to the 1st quartile, the odds ratio for NAFLD was 1.79 (95% C.I. 1.49-2.15, p<0.001) and 3.14 (95% C.I. 2.63-3.75, p<0.001) for the 3rd and 4th quartiles, respectively. After adjusting for demographics, hypertension, waist circumference, triglycerides, high-density lipoprotein-cholesterol, homeostasis model assessment-estimated insulin resistance, estimated glomerular filtration rate, and aspartate aminotransferase, uric acid (4th quartile) was significantly associated with NAFLD (odds ratio 1.43; 95% C.I. 1.16-1.76, p<0.001). Positive parameter estimates suggest increasing uric acid is associated with greater severity of NAFLD. Conclusions: Elevated uric acid level is independently associated with ultrasound-diagnosed NAFLD in a nationally representative sample of United States nondiabetic adults. Increasing uric acid is associated with increasing severity of NAFLD on ultrasonography. These findings warrant further studies on the role of uric acid in NAFLD.
    No preview · Article · Oct 2012 · Metabolism: clinical and experimental
  • [Show abstract] [Hide abstract]
    ABSTRACT: For nearly a century, it is known that hypertension and obesity often coexist. The pathogenetic mechanisms leading to hypertension in obese patients are complex. The most important are: sympathetic nervous system overactivation, increased sodium reabsorption in the renal tubules leading to hypervolemia, insulin resistance, stimulation of the renin-angiotensin- aldosterone system and disturbances of the adipokines secretion. The goal of antihypertensive therapy in obese subjects is to obtain blood pressure below 140/90 mm Hg. Basic methods of antihypertension treatment in obese patients is to reduce body fat mass by calorie restrictive diet and increased physical activity. Recommended for advanced obesity bariatric surgery may also exert an antihypertensive effect. In pharmacotherapy of hypertension in obese patients preferentially are angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists. In order to obtain the target of blood pressure in these patients usually it is necessary to use two or more antihypertensive drugs.
    No preview · Article · Jan 2014 · Nadcisnienie Tetnicze
Show more

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.